Search Results

Pamidronate

Defining PIK3R5-related PI3K gamma dependency as a novel therapeutic target in blood cancers including BPDCN

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive blood cancer without adequate treatment. In a genome-wide CRISPR interference screen, BPDCN was highly dependent on the PI3Kγ pathway and specifically the PIK3R5 adaptor subunit. A subset of leukemias may share this vulnerability. We will interrogate the mechanism of this unique dependency and integrate PIK3R5/PI3Kγ targeting with leukemia therapy. Our goal is to provide novel treatments for PIK3R5-dependent malignancies.

Clinical Trials: Why They Matter and How to Make Them More Accessible

Cancer treatments can be lifesaving. As an organization, The Leukemia & Lymphoma Society (LLS) has invested more than $1.7 billion in blood cancer research since its inception in 1949—all with the hope that this research leads to scientific breakthroughs that improve and save lives.

But to make sure this research leads to safe and innovative treatments, we have to thoroughly test it.

How LLS and Advocates Helped Secure Landmark Health Reforms

Kendra stands against a stone wall, wearing a pink shirt, hiking gear, and a hat.

The hills I have climbed

NCI Genetic Epidemiology Branch- Familial Blood and Lymph Node Cancers

To study families with multiple cases of lymphoproliferative disorders.

The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is studying the causes of familial blood and lymph node cancers. The primary focus is on: Chronic lymphocytic leukemia (CLL), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Waldenstrom’s macroglobulinemia (WM), and Multiple myeloma (MM).
The clinical evaluation includes a medical history and physical examination and may also entail disease-related laboratory or imaging studies. In certain cases, patients may be invited to visit the NIH Warren G. Magnuson Clinical Center in Bethesda, Maryland, for evaluation. Otherwise, study components can often be completed in or near the patient's home community.

Families with 2 or more living individuals in the family with a history of the same lymphoproliferative disorder

800-518-8474 https://dceg.cancer.gov/research/clinical-studies/blood-lymph-cancers

Love, Strength, Support: Sibling care in pediatric blood cancer journeys

Coping with Childhood Blood Cancer: The Power of Play and Creative Therapies for Families

Blood Cancer Patients Need Support Now More Than Ever

Closer to a Cure Inspires & Educates About Treatment Advances of Blood Cancers

Optimizing Clinical Outcomes in Blood Cancers through Groundbreaking Translational Research

LLS Announces Expansion of Precision Medicine Approach to Fight Blood Cancer

FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients

Could Humor Help Your Family Cope with a Blood Cancer Diagnosis?

Innovations in Blood Cancer Treatment: Navigating CAR T-cell and Bispecific Therapies

LLS Unveils Name Change to Reach All Blood Cancer Patients

Impact of State Health Insurance Mandates on Affordability and Utilization of Fertility Preservation in Adolescent and Young Adults with Blood Cancers

Fertility preservation (FP) treatments can prevent infertility caused by blood cancer. However, FP costs are high, and these services are typically not covered by insurance, contributing to low utilization. New state laws require insurers to cover FP, but it is unknown if they improve access to care. Using national insurance data, this study will examine how much out-of-pocket costs remain, whether patients’ share of costs is like that of other cancer services, and whether and which types of laws increase use and affordability.

Filgrastim-sndz

Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:

Patients with cancer receiving myelosuppressive chemotherapy;
Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
Patients with cancer undergoing bone marrow transplantation;
Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
Patients with severe chronic neutropenia.

Filgrastim

Filgrastim is FDA approved to

When The Time Comes: Katie & Phil’s Story

Zoledronic acid

Zoledronic acid is FDA approved to treat hypercalcemia (high levels of blood calcium) that may occur in patients with some types of cancer, including myeloma. It is also FDA approved along with chemotherapy to treat bone damage caused by myeloma or by cancer that began in another part of the body but has spread to the bones.